<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445575</url>
  </required_header>
  <id_info>
    <org_study_id>RBM 03-54</org_study_id>
    <secondary_id>AFSSAPS 060834</secondary_id>
    <nct_id>NCT00445575</nct_id>
  </id_info>
  <brief_title>Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone</brief_title>
  <acronym>PROFIDYS</acronym>
  <official_title>Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is intended to test the efficacy of an oral bisphosphonate (risedronate) to
      decrease bone pain and improve radiological aspect in fibrous dysplasia of bone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In open pilot studies, it has been suggested that bisphosphonates may alleviate bone pain and
      help decrease the surface of osteolytic lesion in patients with fibrous dysplasia of bone
      (FD). So, in this randomized placebo controlled trial, we test the hypothesis that the
      bisphosphonate risedronate reduces bone pain in patients with FD (study I, one year duration)
      and decrease osteolytic lesions (study II, three years duration). Patients will take
      risedronate during 2 months courses, every 6 months or a matching placebo. Dosage will be :
      30mg tablet/day for adults and 5mg tablet x 2,4 according to the age and weight of the child.
      All participants will receive calcium and vitamin D. All patients with renal phosphate
      wasting will receive an oral phosphate supplement.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of bone pain, assessed by visual analogical scale ranging from 0 to 10, on the most painful site.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Surface of osteolytic lesions at three years. Radiological improvement.</measure>
    <time_frame>Three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of biochemical markers of bone turnover at three years</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of painful sites</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>one to three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in bone mineral density of the femoral neck at three years</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Fibrous Dysplasia of Bone</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment duration: 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>treatment duration: 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>duration treatment: 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>treatment duration: 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study I: patients with FD, with bone pain intensity above 3 on visual analogical scale
             from 0 to 10

          -  Study II: patients with FD with at least one osteolytic lesion and no current bone
             pain

        Exclusion Criteria:

          -  patients &lt; 8 years old

          -  other diseases affecting bone metabolism

          -  patients with malignant diseases or other conditions likely to reduce their life
             expectancy to less than 3 years

          -  patients with history of significant upper gastrointestinal disorders

          -  renal failure (creatinine clearance &lt; 25 ml/mn)

          -  severe liver disease

          -  history of iritis or uveitis

          -  rickets or osteomalacia

          -  allergy to bisphosphonates

          -  pregnancy or lactation

          -  prior treatment with a bisphosphonate

          -  laboratory abnormalities that may be considered as clinically significant by trial
             physicians
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ROLAND D CHAPURLAT, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PHILIPPE ORCEL, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOPITAL LARIBOISIERE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SOCRATES D PAPAPOULOS, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ROLAND D CHAPURLAT, MD PhD</last_name>
    <phone>33472117481</phone>
    <email>roland.chapurlat@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CECILE L PELTEKIAN, PhD</last_name>
    <phone>33144236341</phone>
    <email>cecile.peltekian@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEAN PIERRE DEVOGELAER, MD</last_name>
      <phone>3227645390</phone>
      <email>devogelaer@ruma.ucl.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital E Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROLAND D CHAPURLAT, MD PhD</last_name>
      <phone>33472117481</phone>
      <email>roland.chapurlat@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PHILIPPE ORCEL, MD PhD</last_name>
      <phone>33149958631</phone>
      <email>philippe.orcel@lrb.ap-hop.paris.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHRISTIAN ROUX, MD PhD</last_name>
      <phone>33158412584</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DIETER FELSENBERG, MD PhD</last_name>
      <phone>4930844530456</phone>
      <email>dieter.felsenberg@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cologne Clinical Centre</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eckhard SCHÖNAU</last_name>
      <phone>+49 221 4785851</phone>
      <phone_ext>4360</phone_ext>
      <email>Eckhard.schoenau@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heildeberg Clinical Centre</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian KASPERK, MD PhD</last_name>
      <phone>+49 6221 56 86 05</phone>
      <email>Christian.kasperk@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2300</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neveen HAMDY, MD PhD</last_name>
      <phone>31715269111</phone>
      <email>endocrinologie@lume.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.dysplasie-fibreuse-des-os.info/fr/accueil.html</url>
  </link>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2007</study_first_submitted>
  <study_first_submitted_qc>March 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <last_update_submitted>December 29, 2011</last_update_submitted>
  <last_update_submitted_qc>December 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibrous dysplasia of bone</keyword>
  <keyword>Mac Cune Albright syndrome</keyword>
  <keyword>bisphosphonates</keyword>
  <keyword>risedronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Fibrous Dysplasia of Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

